Indian drugmakers to see FY25 revenue boost in key US market, says India Ratings and Research

Keegan Matheson on Blue Jays, Baseball Memories, and More | SaltWire #writer #torontobluejays #mlbHYDERABAD - Indian drugmakers, which have the U.S. market as a key segment, will sustain their revenue improvement in fiscal 2025 due to drug shortages in the United States, Mumbai-based India Ratings and Research said on Monday.

There is an active shortage of 233 drugs across 22 therapeutic categories as of April, led mainly by discontinuing production of some drugs, rising demand and delays in shipments, it said, also citing data from the U.S. Food and Drug Administration. Reddy's reported a 29% jump in North America sales for the most recent quarter ended March 31, while Cipla saw an 11% jump in revenue from the region.India Ratings and Research said increasing regulatory costs led to many US-based generic pharma manufacturers halting the production of certain drugs.

ประเทศไทย ข่าวล่าสุด, ประเทศไทย หัวข้อข่าว

Similar News:คุณยังสามารถอ่านข่าวที่คล้ายกันนี้ซึ่งเรารวบรวมจากแหล่งข่าวอื่น ๆ ได้

Indian drugmakers to see FY25 revenue boost in key US market, says India Ratings and ResearchExplore stories from Atlantic Canada.
แหล่ง: SaltWire Network - 🏆 45. / 63 อ่านเพิ่มเติม »

Emerging-Market Trio Gets Credit-Ratings Boost on Policy TurnsMarkets in three of the largest emerging economies got a boost after Turkey’s sovereign rating was upgraded, and as the outlooks for both Egypt and Nigeria were lifted.
แหล่ง: BNNBloomberg - 🏆 83. / 50 อ่านเพิ่มเติม »